Fouad Atouf, PhD, Chief Science Officer of the United States Pharmacopeia (USP), has underscored the pressing need for evolved standards in biologics development, citing the field's growing complexity. As therapies become more intricate, maintaining product quality, consistency, and patient safety hinges on robust, modernized guidelines.
Atouf, speaking in a Thought Leader piece published in Genetic Engineering News, argued that the current regulatory framework must adapt to keep pace with scientific advances. Biologics, which include monoclonal antibodies and gene therapies, require precise manufacturing controls that are not always addressed by traditional standards.
The push for updated standards comes amid rapid innovation in the biologics space, where novel modalities such as cell and gene therapies are reaching the clinic. Without harmonized benchmarks, variability in production could compromise therapeutic efficacy and pose risks to patients.
While Atouf did not propose specific new standards or timelines, his commentary signals a growing consensus within the industry that voluntary guidance may need to become more prescriptive. USP, a nonprofit scientific organization, develops quality standards for medicines and food ingredients, and its leadership often influences global regulatory approaches.
Counterarguments caution that overly rigid standards could stifle innovation, particularly for emerging platforms where manufacturing best practices are still evolving. Industry stakeholders may push for flexibility to avoid delaying access to transformative therapies.